Johnson & Johnson (JNJ) 101.03 $JNJ
Vertex Pharmaceuticals Incorporated: Profit on the Horizon
Brian Orelli, The Motley Fool - Motley Fool - Sun Nov 01, 9:00AM CST
Vertex Pharmaceuticals released outstanding third-quarter earnings on Wednesday with sales of both cystic fibrosis drugs, Orkambi and Kalydeco, selling like hotcakes. Vertex Pharmaceuticals results: The raw numbers Metric Q3 2015...
JNJ: 101.03 (-0.34), VRTX: 124.74 (-1.43)
ImmunoGen, Inc. Pushes Its Pipeline Forward
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 31, 7:00AM CDT
ImmunoGen reported results from its first fiscal quarter on Tuesday, but there wasn't much to talk about on the financial side. Sales of Kadcyla, the first drug the biotech helped develop, aren't particularly material after ImmunoGen sold the...
JNJ: 101.03 (-0.34), IMGN: 11.70 (+0.16)
NuVasive Straightens Up Its Business With Strong Growth
Dan Caplinger, The Motley Fool - Motley Fool - Fri Oct 30, 6:25PM CDT
Image source: NuVasive. The intersection of technology and healthcare is an exciting place right now, with plenty of innovative solutions designed to treat medical problems and make lives better for the patients who suffer from them. Major...
JNJ: 101.03 (-0.34), NUVA: 47.16 (+0.34)
Why AbbVie Inc. Shares Are Surging 10% Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 30, 1:13PM CDT
Source: AbbVie What: After reporting third quarter financial results that outpaced estimates and issuing long-term financial guidance that stretches out until 2020, shares in AbbVie (NYSE: ABBV) jumped by 10% earlier today. So what: AbbVie...
JNJ: 101.03 (-0.34), ABBV: 59.55 (+5.45)
Johnson & Johnson (JNJ) Approaches New Upside Target of $102.42
Comtex SmarTrend(R) - Fri Oct 30, 9:38AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.01 today and have reached the first resistance level of $101.89. Analysts will be watching for a cross of the next upside pivot targets of $102.42 and $103.83.
JNJ: 101.03 (-0.34)
AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance
at Investor's Business Daily - Fri Oct 30, 9:00AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q3 estimates and issued five-year guidance that was above expectations Friday morning, sending the stock up sharply in early trading. AbbVie's adjusted earnings rose 27% over the year-earlier quarter to $1.13 a...
JNJ: 101.03 (-0.34), PFE: 33.82 (-0.95), AMGN: 158.18 (-2.40), ABBV: 59.55 (+5.45), NVS: 90.43 (-0.53)
Don't Sell Your Allergan Shares Yet, the Stock Could Climb to $350
at The Street - Fri Oct 30, 5:45AM CDT
Shares of Allergan could be valued up to $350 or more in an acquisition, according to one portfolio manager who advises holding the stock for now.
AGN: 308.47 (+4.09), JNJ: 101.03 (-0.34), PFE: 33.82 (-0.95), MRK: 54.66 (-0.21), BMY: 65.95 (-1.36)
Global Knee Osteoarthritis Market 2015 Trends and 2019 Opportunities Discussed in New Research Report
M2 - Fri Oct 30, 5:32AM CDT
MarketReportsOnline.com adds "Global Knee Osteoarthritis Market: Trends and Opportunities (2015-2020)" report to its research store. Knee osteoarthritis is a progressive, degenerative disorder involving the degradation of the intra-articular cartilage, joint lining, ligaments, and the underlying bone of the knee.
JNJ: 101.03 (-0.34), ZBH: 104.57 (-0.30)
Will AbbVie (ABBV) Surprise on Earnings Again in Q3?
Arpita Dutt - Zacks Investment Research - Thu Oct 29, 3:31PM CDT
Focus on AbbVie's (ABBV) third quarter call will be on the performance of key drugs - Humira, Viekira Pak and Imbruvica.
JNJ: 101.03 (-0.34), ESRX: 86.38 (-0.77), GILD: 108.13 (-1.08), SRPT: 24.06 (-0.57), ABBV: 59.55 (+5.45)
These 10 S&P 500 Companies Are the Most Shareholder Friendly
at The Street - Thu Oct 29, 7:40AM CDT
S&P 500 companies are increasingly deploying cash to shareholders via buybacks and dividend payouts. Here are the 10 companies that have returned the most capital over the past 10 years.
JNJ: 101.03 (-0.34), T: 33.51 (-0.04), GE: 28.92 (-0.42), JPM: 64.25 (-0.96), IBM: 140.08 (-0.47), PFE: 33.82 (-0.95), XOM: 82.74 (+0.51), BAC: 16.78 (-0.31), PG: 76.38 (-0.64), MSFT: 52.64 (-0.72)
Research and Markets: Global HIV Drugs Market 2015-2019 - Key Vendors are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck
Business Wire - Wed Oct 28, 12:54PM CDT
Research and Markets (http://www.researchandmarkets.com/research/hck7vp/global_hiv_drugs) has announced the addition of the "Global HIV Drugs Market 2015-2019" report to their offering.
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), GSK: 43.06 (+0.27)
Global Alzheimer Market Report: 2015 Edition
M2 - Wed Oct 28, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmbpv5/global_alzheimer) has announced the addition of the "Global Alzheimer Market Report: 2015 Edition" report to their offering. The report, Global Alzheimer Market analyzes the currently prevailing condition of the market along with its future scope of development. The global market along with specific markets of the U.S., Europe (including the UK) and Asia-Pacific are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth. The current market for Alzheimer's disease drugs is limited as only few drugs have been approved thus, defining a healthy scope of introduction of new drugs in the market in the coming years. The healthcare costs associated with Alzheimer's are also anticipated to rise considerably since only limited treatment options are available in the market. The Alzheimer market expects introduction of innovative small molecules, biopharmaceuticals and disease modifying agents that would help transform the pattern of Alzheimer's disease. Increasing ageing population, growing population of women, rising life expectancy, increasing healthcare expenditure, improving economic conditions, and increasing global spending on medicines are some of the major factors contributing to the growth of Alzheimer's disease market. However, the growth of the market is hindered by certain challenges including lack of availability of effective treatment options, problems in detection and diagnosis, and insufficient research funding. Market Dynamics Growth Drivers - Growing Ageing Population - Increasing Population of Women - Rising Life Expectancy - Rising Healthcare Expenditure - Improving Economic Conditions - Increasing Global Spending on Medicines Key Trends and Developments - Pipeline Drugs under Development - Alzheimer as a Major Cause of Deaths in the U.S. - Development of 5-HT6 Antagonists - Higher Lifetime Risk for Women Challenges - Lack of Effective Treatment Options - Insufficient Research Funding - Difficulty in Detection and Diagnosis Key Topics Covered: 1 Overview 2. Market Analysis 3. Regional Markets 4. Market Dynamics 5. Competitive Landscape 6. Company Profiles - Forest Laboratories, Inc. - Johnson & Johnson - Novartis - Pfizer, Inc. - Roche Holdings For more information visit http://www.researchandmarkets.com/research/lm..._alzheimer
JNJ: 101.03 (-0.34), PFE: 33.82 (-0.95), NVS: 90.43 (-0.53)
Johnson & Johnson to Participate in the 24th Annual Credit Suisse Health Care Conference
M2 - Wed Oct 28, 10:03AM CDT
Johnson & Johnson (NYSE: JNJ) will participate in the 24th Annual Credit Suisse Health Care Conference on Tuesday, Nov. 10, at The Phoenician in Scottsdale, AZ. Dominic Caruso, Vice President, Finance & Chief Financial Officer will represent the Company in a session scheduled at 10:00 a.m. (Mountain Standard Time).
JNJ: 101.03 (-0.34)
This Company's 31-Year Adjusted EPS Growth Streak Will Likely End in 2015
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 28, 8:02AM CDT
Image source: Federal Reserve Bank of New York. Look around the stock market and you'll probably struggle to find a company that's been able to grow its adjusted earnings per share for 10 consecutive years. It's tough because many companies are...
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08)
Global HIV Drugs Market 2015-2019 - Key Vendors are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck
M2 - Wed Oct 28, 7:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4mvfd4/global_hiv_drugs) has announced the addition of the "Global HIV Drugs Market 2015-2019" report to their offering. The global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019. The report, Global HIV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection. Strategic alliances formed between companies, in terms of licensing and collaboration, is a key market trend that is helping co-development and commercialization of drugs in different regions. According to the report, unmet medical needs in the market present significant growth opportunities for vendors. Further, the report states that adverse effects such as hepatotoxicity, hyperglycemia, hyperlipidemia, lactic acidosis, lipodystrophy, osteonecrosis, osteopenia, osteoporosis, and skin rash presents a significant challenge to this market. Based on the class of drugs, the market is segmented as follows: - Multi-class combination products - Nucleoside reverse transcriptase inhibitors - Non-nucleoside reverse transcriptase inhibitors - Protease inhibitors - Fusion inhibitors - Entry inhibitors - CCR5 co-receptor antagonist - HIV integrase strand transfer inhibitors Key vendors - Bristol-Myers Squibb - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck Other prominent vendors - AbbVie - AstraZeneca - Boehringer Ingelheim - Cipla - Daiichi Sankyo - Emcure - F. Hoffmann-La Roche - Hetero Drugs - Mylan - Pfizer - Shionogi - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/4m..._hiv_drugs
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), TEVA: 59.19 (-1.05), GSK: 43.06 (+0.27), BMY: 65.95 (-1.36)
BVGH Accelerates R&D for Neglected Diseases through WIPO Re:Search Collaborations
Business Wire - Wed Oct 28, 4:23AM CDT
BIO Ventures for Global Health (BVGH) today released its second compilation of WIPO Re:Search collaboration stories featuring partnerships accelerating neglected disease research. WIPO Re:Search, established by the World Intellectual Property Organization in partnership with BVGH and several leading pharmaceutical companies, brings scientists from academia and biopharmaceutical companies together to develop new therapies for diseases centered in developing nations. BVGH initiates these partnerships by identifying relevant research assets in pharmaceutical companies and matches them with academic researchers working on neglected tropical diseases. African researchers and institutions play a significant role in a number of the partnerships featured in this story book.
JNJ: 101.03 (-0.34), MRK: 54.66 (-0.21)
Global Cephalosporin Drugs Market 2015-2019 - Special Regulatory Designation for Pipeline Molecules a Key Market Driver
M2 - Tue Oct 27, 10:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sgkt3b/global) has announced the addition of the "Global Cephalosporin Drugs Market 2015-2019" report to their offering. The global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019 The report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The increased approvals and use of combination drugs is an emerging trend in the global cephalosporin drugs market. Combination therapies are found to show better efficacy than monotherapies. Also, the use of monotherapies leads to easy development of resistance. This can be avoided by the judicious use of combination drugs. According to the report, the increased awareness of diseases and their treatment options helps detect and treat infections during their early stages. The European Antibiotic Awareness Day is celebrated on November 18 every year to raise awareness about antibiotic resistance and promote the judicious use of antibiotics. Such programs about the disease and treatment options increase the treatment-seeking population, driving the growth of the market. Further, the report states that most drugs in the cephalosporin market are generics, resulting in decreased revenue for the products. Some drugs that have expired and have a generic form as of today include cefuroxime axetil, ceftazidime, and cefprozil. Key vendors - Allergan - Astellas - Bristol-Myers Squibb - GlaxoSmithKline - Merck - Pfizer - Sandoz - Teva Pharmaceuticals Other prominent vendors - Abbott - Aspen Pharmacare - AstraZeneca - Aurobindo Pharma - Basilea Pharmaceuticals - Baxter - Biocon - Corden Pharma - Cornerstone Therapeutics - Eli Lilly - F. Hoffmann-La Roche - Flynn Pharma - Hospira - Incepta Pharmaceuticals - Johnson & Johnson - Kyorin Pharmaceutical - Lupin Pharmaceuticals - Orchid Pharma - Par Pharmaceutical - Pernix Therapeutics - Sanofi - Shionogi - Sun Pharmaceutical - Takeda Pharma - Theravance Biopharma - Wockhardt Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Cephalosporin overview Part 06: Overview on the consumption of antibiotics Part 07: Legislation relating to antibiotic use in the US Part 08: Market landscape Part 09: Market segmentation by generation of cephalosporin Part 10: Market segmentation by route of administration Part 11: Geographical segmentation Part 12: Market drivers Part 13: Impact of drivers Part 14: Market challenges Part 15: Impact of drivers and challenges Part 16: Market trends Part 17: Vendor landscape Part 18: Key vendor analysis For more information visit http://www.researchandmarkets.com/research/sgkt3b/global
AGN: 308.47 (+4.09), JNJ: 101.03 (-0.34), MRK: 54.66 (-0.21), LLY: 81.57 (-0.43), TBPH: 14.95 (+0.31), GSK: 43.06 (+0.27), BMY: 65.95 (-1.36)
Neurovascular Devices/Interventional Neurology Market by Technology (Embolization, Carotid Stenting, Balloon Angioplasty, Neurothrombectomy), Product - Global Forecast to 2020
M2 - Tue Oct 27, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db69wx/neurovascular) has announced the addition of the "Neurovascular Devices/Interventional Neurology Market by Technology (Embolization, Carotid Stenting, Balloon Angioplasty, Neurothrombectomy), Product - Global Forecast to 2020 " report to their offering. The global neurovascular devices/interventional neurology market is poised to reach -$2,370.4 million by 2020, growing at a CAGR of 8.4% from 2015 to 2020 North America is expected to hold the largest share of 47.3% of the global market in 2015. Market growth is being propelled by growing target patient population, technological advancements in the field of interventional neurosurgeries, favorable medical reimbursement scenario across mature markets, and expanding healthcare infrastructure in developing countries. However, factors such as ongoing healthcare reforms in the U.S. and a dearth of skilled neurosurgeons are restraining the growth of this market. In addition, stringent regulatory policies (that regulate product development and commercialization) across major markets are posing significant challenges for the growth of the neurovascular devices/interventional neurology market during the forecast period. In this report, the global neurovascular devices/interventional neurology market is segmented on the basis of technology (embolization & coiling, carotid artery angioplasty & stenting, supporting techniques, and neurothrombectomy) and product (cerebral balloon angioplasty & stenting systems, aneurysm coiling & embolization devices, support devices, and neurothrombectomy devices). The aneurysm coiling and embolization devices segment is expected to account for the largest share of the global neurovascular devices/interventional neurology market in 2015, followed by cerebral balloon angioplasty & stenting systems. The cerebral balloon angioplasty & stenting systems segment is expected to grow at the highest CAGR during the next five years owing to factors such as an increasing number of researches, rising public-private funding to develop novel carotid stents & occlusion catheter products, and growing availability of technologically advanced stents & embolic protection devices across major markets (such as Europe, Japan, and the U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Neurovascular Devices/Interventional Neurology Market 7 Neurovascular Devices/Interventional Neurology Market 8 Neurovascular Devices/Interventional Neurology Market 9 Competitive Landscape 10 Company Profiles - Abbott Laboratories - Geographic Mix - Johnson & Johnson - Medikit Co., Ltd. - Medtronic Plc - Merit Medical Systems, Inc. - Microport Scientific Corporation - Penumbra, Inc. - Strategic Benchmarking - Stryker Corporation - Terumo Corporation - W. L. Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/db...rovascular
JNJ: 101.03 (-0.34), ABT: 44.80 (-0.44), MDT: 73.92 (+0.16), PEN: 37.03 (-0.76), MMSI: 18.54 (-0.68), SYK: 95.62 (-0.23)
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
Business Wire - Tue Oct 27, 6:00AM CDT
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, announced the appointment of Dr. Miguel Barbosa, Ph.D. as Executive Vice President and Chief Scientific Officer.
JNJ: 101.03 (-0.34), MIRN: 5.78 (-0.15)
Vertex Pharmaceuticals Incorporated: Profit on the Horizon
Brian Orelli, The Motley Fool - Motley Fool - Sun Nov 01, 9:00AM CST
Vertex Pharmaceuticals released outstanding third-quarter earnings on Wednesday with sales of both cystic fibrosis drugs, Orkambi and Kalydeco, selling like hotcakes. Vertex Pharmaceuticals results: The raw numbers Metric Q3 2015...
JNJ: 101.03 (-0.34), VRTX: 124.74 (-1.43)
ImmunoGen, Inc. Pushes Its Pipeline Forward
Brian Orelli, The Motley Fool - Motley Fool - Sat Oct 31, 7:00AM CDT
ImmunoGen reported results from its first fiscal quarter on Tuesday, but there wasn't much to talk about on the financial side. Sales of Kadcyla, the first drug the biotech helped develop, aren't particularly material after ImmunoGen sold the...
JNJ: 101.03 (-0.34), IMGN: 11.70 (+0.16)
NuVasive Straightens Up Its Business With Strong Growth
Dan Caplinger, The Motley Fool - Motley Fool - Fri Oct 30, 6:25PM CDT
Image source: NuVasive. The intersection of technology and healthcare is an exciting place right now, with plenty of innovative solutions designed to treat medical problems and make lives better for the patients who suffer from them. Major...
JNJ: 101.03 (-0.34), NUVA: 47.16 (+0.34)
Why AbbVie Inc. Shares Are Surging 10% Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 30, 1:13PM CDT
Source: AbbVie What: After reporting third quarter financial results that outpaced estimates and issuing long-term financial guidance that stretches out until 2020, shares in AbbVie (NYSE: ABBV) jumped by 10% earlier today. So what: AbbVie...
JNJ: 101.03 (-0.34), ABBV: 59.55 (+5.45)
Johnson & Johnson (JNJ) Approaches New Upside Target of $102.42
Comtex SmarTrend(R) - Fri Oct 30, 9:38AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.01 today and have reached the first resistance level of $101.89. Analysts will be watching for a cross of the next upside pivot targets of $102.42 and $103.83.
JNJ: 101.03 (-0.34)
AbbVie Beats Q3 Views, Offers Bullish 2020 Guidance
at Investor's Business Daily - Fri Oct 30, 9:00AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q3 estimates and issued five-year guidance that was above expectations Friday morning, sending the stock up sharply in early trading. AbbVie's adjusted earnings rose 27% over the year-earlier quarter to $1.13 a...
JNJ: 101.03 (-0.34), PFE: 33.82 (-0.95), AMGN: 158.18 (-2.40), ABBV: 59.55 (+5.45), NVS: 90.43 (-0.53)
Don't Sell Your Allergan Shares Yet, the Stock Could Climb to $350
at The Street - Fri Oct 30, 5:45AM CDT
Shares of Allergan could be valued up to $350 or more in an acquisition, according to one portfolio manager who advises holding the stock for now.
AGN: 308.47 (+4.09), JNJ: 101.03 (-0.34), PFE: 33.82 (-0.95), MRK: 54.66 (-0.21), BMY: 65.95 (-1.36)
Global Knee Osteoarthritis Market 2015 Trends and 2019 Opportunities Discussed in New Research Report
M2 - Fri Oct 30, 5:32AM CDT
MarketReportsOnline.com adds "Global Knee Osteoarthritis Market: Trends and Opportunities (2015-2020)" report to its research store. Knee osteoarthritis is a progressive, degenerative disorder involving the degradation of the intra-articular cartilage, joint lining, ligaments, and the underlying bone of the knee.
JNJ: 101.03 (-0.34), ZBH: 104.57 (-0.30)
Will AbbVie (ABBV) Surprise on Earnings Again in Q3?
Arpita Dutt - Zacks Investment Research - Thu Oct 29, 3:31PM CDT
Focus on AbbVie's (ABBV) third quarter call will be on the performance of key drugs - Humira, Viekira Pak and Imbruvica.
JNJ: 101.03 (-0.34), ESRX: 86.38 (-0.77), GILD: 108.13 (-1.08), SRPT: 24.06 (-0.57), ABBV: 59.55 (+5.45)
These 10 S&P 500 Companies Are the Most Shareholder Friendly
at The Street - Thu Oct 29, 7:40AM CDT
S&P 500 companies are increasingly deploying cash to shareholders via buybacks and dividend payouts. Here are the 10 companies that have returned the most capital over the past 10 years.
JNJ: 101.03 (-0.34), T: 33.51 (-0.04), GE: 28.92 (-0.42), JPM: 64.25 (-0.96), IBM: 140.08 (-0.47), PFE: 33.82 (-0.95), XOM: 82.74 (+0.51), BAC: 16.78 (-0.31), PG: 76.38 (-0.64), MSFT: 52.64 (-0.72)
Research and Markets: Global HIV Drugs Market 2015-2019 - Key Vendors are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck
Business Wire - Wed Oct 28, 12:54PM CDT
Research and Markets (http://www.researchandmarkets.com/research/hck7vp/global_hiv_drugs) has announced the addition of the "Global HIV Drugs Market 2015-2019" report to their offering.
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), GSK: 43.06 (+0.27)
Global Alzheimer Market Report: 2015 Edition
M2 - Wed Oct 28, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmbpv5/global_alzheimer) has announced the addition of the "Global Alzheimer Market Report: 2015 Edition" report to their offering. The report, Global Alzheimer Market analyzes the currently prevailing condition of the market along with its future scope of development. The global market along with specific markets of the U.S., Europe (including the UK) and Asia-Pacific are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth. The current market for Alzheimer's disease drugs is limited as only few drugs have been approved thus, defining a healthy scope of introduction of new drugs in the market in the coming years. The healthcare costs associated with Alzheimer's are also anticipated to rise considerably since only limited treatment options are available in the market. The Alzheimer market expects introduction of innovative small molecules, biopharmaceuticals and disease modifying agents that would help transform the pattern of Alzheimer's disease. Increasing ageing population, growing population of women, rising life expectancy, increasing healthcare expenditure, improving economic conditions, and increasing global spending on medicines are some of the major factors contributing to the growth of Alzheimer's disease market. However, the growth of the market is hindered by certain challenges including lack of availability of effective treatment options, problems in detection and diagnosis, and insufficient research funding. Market Dynamics Growth Drivers - Growing Ageing Population - Increasing Population of Women - Rising Life Expectancy - Rising Healthcare Expenditure - Improving Economic Conditions - Increasing Global Spending on Medicines Key Trends and Developments - Pipeline Drugs under Development - Alzheimer as a Major Cause of Deaths in the U.S. - Development of 5-HT6 Antagonists - Higher Lifetime Risk for Women Challenges - Lack of Effective Treatment Options - Insufficient Research Funding - Difficulty in Detection and Diagnosis Key Topics Covered: 1 Overview 2. Market Analysis 3. Regional Markets 4. Market Dynamics 5. Competitive Landscape 6. Company Profiles - Forest Laboratories, Inc. - Johnson & Johnson - Novartis - Pfizer, Inc. - Roche Holdings For more information visit http://www.researchandmarkets.com/research/lm..._alzheimer
JNJ: 101.03 (-0.34), PFE: 33.82 (-0.95), NVS: 90.43 (-0.53)
Johnson & Johnson to Participate in the 24th Annual Credit Suisse Health Care Conference
M2 - Wed Oct 28, 10:03AM CDT
Johnson & Johnson (NYSE: JNJ) will participate in the 24th Annual Credit Suisse Health Care Conference on Tuesday, Nov. 10, at The Phoenician in Scottsdale, AZ. Dominic Caruso, Vice President, Finance & Chief Financial Officer will represent the Company in a session scheduled at 10:00 a.m. (Mountain Standard Time).
JNJ: 101.03 (-0.34)
This Company's 31-Year Adjusted EPS Growth Streak Will Likely End in 2015
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 28, 8:02AM CDT
Image source: Federal Reserve Bank of New York. Look around the stock market and you'll probably struggle to find a company that's been able to grow its adjusted earnings per share for 10 consecutive years. It's tough because many companies are...
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08)
Global HIV Drugs Market 2015-2019 - Key Vendors are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck
M2 - Wed Oct 28, 7:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4mvfd4/global_hiv_drugs) has announced the addition of the "Global HIV Drugs Market 2015-2019" report to their offering. The global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019. The report, Global HIV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection. Strategic alliances formed between companies, in terms of licensing and collaboration, is a key market trend that is helping co-development and commercialization of drugs in different regions. According to the report, unmet medical needs in the market present significant growth opportunities for vendors. Further, the report states that adverse effects such as hepatotoxicity, hyperglycemia, hyperlipidemia, lactic acidosis, lipodystrophy, osteonecrosis, osteopenia, osteoporosis, and skin rash presents a significant challenge to this market. Based on the class of drugs, the market is segmented as follows: - Multi-class combination products - Nucleoside reverse transcriptase inhibitors - Non-nucleoside reverse transcriptase inhibitors - Protease inhibitors - Fusion inhibitors - Entry inhibitors - CCR5 co-receptor antagonist - HIV integrase strand transfer inhibitors Key vendors - Bristol-Myers Squibb - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck Other prominent vendors - AbbVie - AstraZeneca - Boehringer Ingelheim - Cipla - Daiichi Sankyo - Emcure - F. Hoffmann-La Roche - Hetero Drugs - Mylan - Pfizer - Shionogi - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/4m..._hiv_drugs
JNJ: 101.03 (-0.34), GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), TEVA: 59.19 (-1.05), GSK: 43.06 (+0.27), BMY: 65.95 (-1.36)
BVGH Accelerates R&D for Neglected Diseases through WIPO Re:Search Collaborations
Business Wire - Wed Oct 28, 4:23AM CDT
BIO Ventures for Global Health (BVGH) today released its second compilation of WIPO Re:Search collaboration stories featuring partnerships accelerating neglected disease research. WIPO Re:Search, established by the World Intellectual Property Organization in partnership with BVGH and several leading pharmaceutical companies, brings scientists from academia and biopharmaceutical companies together to develop new therapies for diseases centered in developing nations. BVGH initiates these partnerships by identifying relevant research assets in pharmaceutical companies and matches them with academic researchers working on neglected tropical diseases. African researchers and institutions play a significant role in a number of the partnerships featured in this story book.
JNJ: 101.03 (-0.34), MRK: 54.66 (-0.21)
Global Cephalosporin Drugs Market 2015-2019 - Special Regulatory Designation for Pipeline Molecules a Key Market Driver
M2 - Tue Oct 27, 10:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sgkt3b/global) has announced the addition of the "Global Cephalosporin Drugs Market 2015-2019" report to their offering. The global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019 The report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The increased approvals and use of combination drugs is an emerging trend in the global cephalosporin drugs market. Combination therapies are found to show better efficacy than monotherapies. Also, the use of monotherapies leads to easy development of resistance. This can be avoided by the judicious use of combination drugs. According to the report, the increased awareness of diseases and their treatment options helps detect and treat infections during their early stages. The European Antibiotic Awareness Day is celebrated on November 18 every year to raise awareness about antibiotic resistance and promote the judicious use of antibiotics. Such programs about the disease and treatment options increase the treatment-seeking population, driving the growth of the market. Further, the report states that most drugs in the cephalosporin market are generics, resulting in decreased revenue for the products. Some drugs that have expired and have a generic form as of today include cefuroxime axetil, ceftazidime, and cefprozil. Key vendors - Allergan - Astellas - Bristol-Myers Squibb - GlaxoSmithKline - Merck - Pfizer - Sandoz - Teva Pharmaceuticals Other prominent vendors - Abbott - Aspen Pharmacare - AstraZeneca - Aurobindo Pharma - Basilea Pharmaceuticals - Baxter - Biocon - Corden Pharma - Cornerstone Therapeutics - Eli Lilly - F. Hoffmann-La Roche - Flynn Pharma - Hospira - Incepta Pharmaceuticals - Johnson & Johnson - Kyorin Pharmaceutical - Lupin Pharmaceuticals - Orchid Pharma - Par Pharmaceutical - Pernix Therapeutics - Sanofi - Shionogi - Sun Pharmaceutical - Takeda Pharma - Theravance Biopharma - Wockhardt Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Cephalosporin overview Part 06: Overview on the consumption of antibiotics Part 07: Legislation relating to antibiotic use in the US Part 08: Market landscape Part 09: Market segmentation by generation of cephalosporin Part 10: Market segmentation by route of administration Part 11: Geographical segmentation Part 12: Market drivers Part 13: Impact of drivers Part 14: Market challenges Part 15: Impact of drivers and challenges Part 16: Market trends Part 17: Vendor landscape Part 18: Key vendor analysis For more information visit http://www.researchandmarkets.com/research/sgkt3b/global
AGN: 308.47 (+4.09), JNJ: 101.03 (-0.34), MRK: 54.66 (-0.21), LLY: 81.57 (-0.43), TBPH: 14.95 (+0.31), GSK: 43.06 (+0.27), BMY: 65.95 (-1.36)
Neurovascular Devices/Interventional Neurology Market by Technology (Embolization, Carotid Stenting, Balloon Angioplasty, Neurothrombectomy), Product - Global Forecast to 2020
M2 - Tue Oct 27, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db69wx/neurovascular) has announced the addition of the "Neurovascular Devices/Interventional Neurology Market by Technology (Embolization, Carotid Stenting, Balloon Angioplasty, Neurothrombectomy), Product - Global Forecast to 2020 " report to their offering. The global neurovascular devices/interventional neurology market is poised to reach -$2,370.4 million by 2020, growing at a CAGR of 8.4% from 2015 to 2020 North America is expected to hold the largest share of 47.3% of the global market in 2015. Market growth is being propelled by growing target patient population, technological advancements in the field of interventional neurosurgeries, favorable medical reimbursement scenario across mature markets, and expanding healthcare infrastructure in developing countries. However, factors such as ongoing healthcare reforms in the U.S. and a dearth of skilled neurosurgeons are restraining the growth of this market. In addition, stringent regulatory policies (that regulate product development and commercialization) across major markets are posing significant challenges for the growth of the neurovascular devices/interventional neurology market during the forecast period. In this report, the global neurovascular devices/interventional neurology market is segmented on the basis of technology (embolization & coiling, carotid artery angioplasty & stenting, supporting techniques, and neurothrombectomy) and product (cerebral balloon angioplasty & stenting systems, aneurysm coiling & embolization devices, support devices, and neurothrombectomy devices). The aneurysm coiling and embolization devices segment is expected to account for the largest share of the global neurovascular devices/interventional neurology market in 2015, followed by cerebral balloon angioplasty & stenting systems. The cerebral balloon angioplasty & stenting systems segment is expected to grow at the highest CAGR during the next five years owing to factors such as an increasing number of researches, rising public-private funding to develop novel carotid stents & occlusion catheter products, and growing availability of technologically advanced stents & embolic protection devices across major markets (such as Europe, Japan, and the U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Neurovascular Devices/Interventional Neurology Market 7 Neurovascular Devices/Interventional Neurology Market 8 Neurovascular Devices/Interventional Neurology Market 9 Competitive Landscape 10 Company Profiles - Abbott Laboratories - Geographic Mix - Johnson & Johnson - Medikit Co., Ltd. - Medtronic Plc - Merit Medical Systems, Inc. - Microport Scientific Corporation - Penumbra, Inc. - Strategic Benchmarking - Stryker Corporation - Terumo Corporation - W. L. Gore & Associates, Inc. For more information visit http://www.researchandmarkets.com/research/db...rovascular
JNJ: 101.03 (-0.34), ABT: 44.80 (-0.44), MDT: 73.92 (+0.16), PEN: 37.03 (-0.76), MMSI: 18.54 (-0.68), SYK: 95.62 (-0.23)
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
Business Wire - Tue Oct 27, 6:00AM CDT
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, announced the appointment of Dr. Miguel Barbosa, Ph.D. as Executive Vice President and Chief Scientific Officer.
JNJ: 101.03 (-0.34), MIRN: 5.78 (-0.15)
